GlassScriptPhysician profile
Jonathan F Greene
NPI 1821032285
$10,143.63
in general payments reported to CMS, 2019-2025
48 companies · $1,469 in 2025
The $1,469 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,382 · 2020: $355 · 2021: $1,772 · 2022: $2,130 · 2023: $1,800 · 2024: $1,236 · 2025: $1,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,504.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,324.95 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $1,198.72 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $931.59 | 2019-2025 | |
| Novo Nordisk INC | $842.71 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $805.88 | 2019-2025 | |
| Glaxosmithkline, LLC. | $757.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $605.00 | 2019-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $457.43 | 2022-2025 | |
| Amgen INC. | $453.56 | 2019-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $335.86 | 2019-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $251.03 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $230.80 | 2019-2023 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $202.48 | 2019-2023 | Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $193.76 | 2019-2022 | |
| Intra-Sana Laboratories | $191.81 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.